Æterna Zentaris Margine di operatività
Cos'è Margine di operatività di Æterna Zentaris?
Margine di operatività di Æterna Zentaris, Inc. è -837.68%
Qual è la definizione di Margine di operatività?
Il margine operativo è il rapporto tra il reddito operativo diviso per le vendite nette e presentato in percentuale.
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
Margine di operatività di aziende nel Health Care settore su TSX rispetto a Æterna Zentaris
Cosa fa Æterna Zentaris?
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aziende con margine di operatività simili a Æterna Zentaris
- MinRex Resources ha Margine di operatività di -857.14%
- New World Resources ha Margine di operatività di -853.10%
- EHang Ltd ha Margine di operatività di -851.38%
- Modern Meat ha Margine di operatività di -850.14%
- Aravive Inc ha Margine di operatività di -847.42%
- Acerus Pharmaceuticals ha Margine di operatività di -840.78%
- Æterna Zentaris ha Margine di operatività di -837.68%
- Menlo Therapeutics ha Margine di operatività di -836.40%
- Redwood Green ha Margine di operatività di -836.24%
- Nvoi ha Margine di operatività di -835.47%
- OncoSil Medical ha Margine di operatività di -833.56%
- Lianluo Smart Ltd ha Margine di operatività di -829.80%
- Cyprium Metals ha Margine di operatività di -826.05%